Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reversal of Moderate (With the Use of Neostigmine 60 mcg/kg) or Superficial (With the Use of Neostigmine 30 mcg/kg) Neuromuscular Blockade Induced by Cisatracurium. A Prospective, Randomized, Controlled and Doubled Blinded Clinical Trial

NCT04920682 is registered in ClinicalTrials.gov with Pontificia Universidade Catolica de Sao Paulo as lead sponsor.

NCT NCT04920682
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04920682 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reversal of Moderate (With the Use of Neostigmine 60 mcg/kg) or Superficial (With the Use of Neostigmine 30 mcg/kg) Neuromuscular Blockade Induced by Cisatracurium. A Prospective, Randomized, Controlled and Doubled Blinded Clinical Trial
Lead sponsor
Pontificia Universidade Catolica de Sao Paulo
Phase
Phase 4
Overall status
Completed
Start date
June 1, 2021
Completion date
August 21, 2021
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

muscle weakness, neostigmine, neuromuscular blocking agents